This gene is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignancies and disease that involve this region as well as the transport of chloroquine- and quinidine-related compounds in the kidney. Two alternative transcripts encoding the same isoform have been described.[7]
Akiyama S (December 2001). "[Mechanisms of drug resistance and reversal of the resistance]". Human Cell. 14 (4): 257–60. PMID11925925.
Cooper PR, Smilinich NJ, Day CD, Nowak NJ, Reid LH, Pearsall RS, Reece M, Prawitt D, Landers J, Housman DE, Winterpacht A, Zabel BU, Pelletier J, Weissman BE, Shows TB, Higgins MJ (April 1998). "Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain". Genomics. 49 (1): 38–51. doi:10.1006/geno.1998.5221. PMID9570947.
Lee MP, Reeves C, Schmitt A, Su K, Connors TD, Hu RJ, Brandenburg S, Lee MJ, Miller G, Feinberg AP (September 1998). "Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5". Cancer Research. 58 (18): 4155–9. PMID9751628.
Gallagher E, Mc Goldrick A, Chung WY, Mc Cormack O, Harrison M, Kerin M, Dervan PA, Mc Cann A (July 2006). "Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer". Genomics. 88 (1): 12–7. doi:10.1016/j.ygeno.2006.02.004. PMID16624517.